Stakeholders Urge Major Changes To Australia's PBS Listing Guidelines
This article was originally published in SRA
Executive Summary
The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing1,2.